A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

Inclusion Criteria: * Male healthy subjects and male asthma patients aged 18 to 45 years (inclusive) * Have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive and rounding allowed) and weight between 50 and 100 kg (inclusive) * Be able to inhale from the SPIRA nebuliser and I-neb® according to the provided instructions * Asthma patients should fulfil the following criteria: Pre-bronchodilator forced expiratory volume at 1 second (FEV1) ≥70% of predicted normal value * Asthma diagnosis according to GINA guidelines with a history of episodic wheeze and shortness of breath Exclusion Criteria: * History of any clinically significant disease or disorder * Any clinically relevant abnormal findings * Current smokers * Asthma patients: Worsening of asthma or respiratory infection within 6 weeks before screening * Asthma patients: Use of inhaled, nasal, oral, rectal or parenteral corticosteroids within 30 days before first administration of investigational product and during the study